BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025
Company to host conference call at 8 a.m. ET, August 27, 2025
Company to host conference call at 8 a.m. ET, August 27, 2025
Related Questions
What are the expected market implications of the SERENITY trial topline results on BioXcel's valuation?
How does the efficacy and safety data from SERENITY compare to existing treatments for agitation in bipolar disorder and schizophrenia?
What potential does this trial success have to expand BioXcel's pipeline and partnership opportunities?